AxerlaRx

AxerlaRx is a clinical-stage biotechnology company and contract research organization (CRO) specializing in molecular imaging and fluorescence-guided imaging (FGI). Based in Groningen, Netherlands, and closely integrated with TRACER Europe B.V., the company focuses on the development and clinical validation of targeted fluorescent tracers to improve surgical outcomes and drug development. Its lead programs include cetuximab-800CW for real-time resection margin evaluation in head and neck cancer and EMI-137 for Barrett's esophagus. AxerlaRx provides a comprehensive platform for imaging drug binding and biodistribution, supporting pharmaceutical partners in early-phase clinical trials. The company's expertise spans from GMP tracer production to advanced spectroscopic quantification in the operating room.